Valo Health

Valo Health is a technology-driven biopharmaceutical company dedicated to transforming the drug discovery and development process through AI-powered integration of large-scale human data. The company’s mission is to unify every stage of drug development — from target identification to clinical design — within a single, intelligent computational architecture. This approach aims to reduce the cost, duration, and failure rate of drug development while accelerating the delivery of new treatments to patients.

Corporate Vision and Structure

Valo Health’s strategy centers on creating a digitally integrated ecosystem for human-centric drug discovery. By combining human biological data with advanced machine learning algorithms, Valo’s platform is designed to predict disease progression, simulate drug mechanisms, and optimize clinical trial design.

This human data–driven model enables Valo to focus on translational relevance and predictive accuracy, bridging the gap between computational research and clinical outcomes.

Technology Foundation: Opal Computational Platform™

At the core of Valo Health’s innovation lies the Opal Computational Platform™, a closed-loop system that continuously integrates and refines multi-scale biological and clinical data.

Opal connects the full lifecycle of drug discovery — including target identification, molecule design, preclinical evaluation, and clinical trial optimization — while self-improving through ongoing data feedback.

Key Components:

• Multi-omics Integration: Combines genetic, biochemical, and clinical datasets to discover disease mechanisms.
• Predictive Modeling: Uses AI to forecast drug efficacy, safety, and disease trajectories.
• Biowire™ Technology: Produces lab-grown biological models mimicking human tissue, allowing high-fidelity testing of drug compounds in physiologically relevant environments.

Research Focus and Collaborations

Valo Health’s R&D programs span cardiovascular, metabolic, renal, oncological, and neurodegenerative diseases.

Key Collaborations:

• Logica® Platform (with Charles River Laboratories): Integrates target identification, screening, and lead optimization into a unified, automated pipeline for early-stage discovery.
• Kahn-Sagol-Maccabi Research & Innovation Institute (KSM), Israel: Long-term partnership applying the Opal platform to complex disease modeling and precision therapeutic development.
• Michael J. Fox Foundation (2025): Funding to support Parkinson’s disease research using Valo’s AI-based drug discovery system.

Leadership and Organization

Executive Team:

• Dr. Brian Alexander – Chief Executive Officer (CEO)
• Dr. Brett Blackman – Chief Operating Officer (COO)
• Dr. Michael Graziano – Chief Scientific Officer (CSO)
• Guido Lanza – Chief Technology Officer (CTO)

Board of Directors:

• Paul Biondi – Chairman of the Board
• Members representing biotechnology, venture capital, and data science sectors

Vision and Impact

Valo Health aims to establish AI-driven computational systems as the new standard in global drug development. By integrating biology, computation, and human clinical data, Valo seeks to transform R&D into a faster, more predictive, and scalable process, making precision medicine accessible at unprecedented speed and efficiency.